Kisspeptin-10

Also known as: Kisspeptin, KP-10, Metastin Fragment

A fragment of kisspeptin that stimulates GnRH release for reproductive function.

Overview

Kisspeptin-10 is a decapeptide fragment of the full kisspeptin protein that plays a critical role in reproductive function. It stimulates GnRH release from the hypothalamus, triggering the HPG axis. It is being researched for infertility, hypogonadism, and as an alternative to GnRH agonists.

Mechanism of Action

Binds to KISS1R (GPR54) on GnRH neurons, stimulating GnRH release. This triggers pituitary LH and FSH secretion, ultimately increasing sex hormone production. Acts as master regulator of reproductive axis.

Pharmacokinetics

Very short half-life (~30 minutes). IV or SubQ administration. Rapid effects on LH pulse.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

LH Stimulation

Dose

1-10 nmol/kg

Frequency

Single or repeated doses

Duration

Acute use

Research protocols

2

IVF Trigger

Dose

Variable

Frequency

Single dose

Duration

Once

Alternative to hCG trigger

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: HPG axis

Synergy: Different levels of axis stimulation

Research Areas

Reproductive FunctionInfertilityHypogonadismIVFPuberty DisordersSexual Function

Key Research Findings

  • 1Master regulator of GnRH release
  • 2Stimulates LH pulse within minutes
  • 3Alternative to GnRH for IVF trigger
  • 4Potential for hypogonadism treatment

Side Effects & Contraindications

Reported Side Effects

  • Hot flashes
  • Headache
  • Nausea
  • Abdominal discomfort

Contraindications

  • Pregnancy
  • Sex hormone-sensitive cancers

Safety Considerations

Research compound for most uses. Short half-life limits practical application. Being studied for IVF protocols.

Storage Requirements

Store at -20C

Scientific References

Quick Reference

Sequence
Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Molecular Weight
1302 g/mol
Half-Life
~30 minutes
Bioavailability
Injectable
Research Stage
clinical phase 2
Administration
Subcutaneous or IV